Utilizing already existing drugs for novel treatments gives several advantages, such as having a much lower risk of failure, safety, and more attractive pricing capabilities. Focusing on just the IPF market alone, it’s valued at around $4.7B growing at a GAGR of 6.9%. This provides $AGN.C with a significant market potential when considering that there are only 2 approved treatments costing upwards of $100,000. People are actively looking for cheaper treatments, so $AGN.C’s Ifenprodil could have a significant future ahead now that phase 2a trials have already shown safety and potential as they reached statistical significance with 65% of IPF trial participants showing an improved vital capacity versus the 40% placebo and a reduction in the geometric mean for coughs in the chronic cough study.
When considering they’re also planning on conducting multiple phase 1 trials for DMT for stroke, Reprinast for chronic kidney disease, and additional uses of Ifenprodil in Q4, there are a lot of upcoming research catalysts for $AGN.C. Pre-clinical/study results have already shown promise:
- Research has shown DMT has Neuroplastic and Neurogenesis growth effects.
- Fibrosis reduction in the kidney from reprinast.
Overall, the team is extremely experienced and are targeting multiple billion-dollar markets. With the stock continuing to consolidate after last week’s push, and an RSI of just 36, it’s safe to say this is oversold, especially with a valuation of $7.2M.